Structure Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and UnitedHealth (UNH)
Structure Therapeutics Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
Structure Therapeutics Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
Structure Therapeutics (NASDAQ:GPCR): Analysts Say This GLP-1 Stock Can Rise 130%
Buy Rating on Structure Therapeutics' GSBR-1290 for Non-T2D Obesity Potential
Structure Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), 4D Molecular Therapeutics (FDMT) and Sanofi (OtherSNYNF)
Structure Therapeutics Analyst Ratings
J.P. Morgan Securities: Reiterated the Structure Therapeutics (GPCR.US) rating and adjusted from superior to superior market rating, with a target price of $91.00.
Buy Rating for Structure Therapeutics: Promising Pipeline and Financial Stability Ahead of Key Clinical Data Release
Structure Therapeutics Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
Analysts Are Bullish on These Healthcare Stocks: Corcept Therapeutics (CORT), Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Structure Therapeutics Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
Buy Rating Affirmed for Structure Therapeutics on Upcoming GSBR-1290 Phase 2a Data Optimism
Buy Rating for Structure Therapeutics on Strong Obesity Drug Prospects and Strategic Partnerships